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Summary: The Boehringer Mannheim Hitachi 911 is a selective analyzer for 35 different methods including 3 ion-
selective electrode (ISE) methods. We have evaluated this analyzer primarily to obtain objective information on its
applicability for routine urine analyses in our laboratory. We also implemented appropriate assays for various
special serum- and whole blood-tests, some for the first time on the Hitachi 911 and some with modified settings.
Analytical evaluation involved NCCLS EP5-T2 (imprecision), NCCLS EP6-P (linearity), Krouwer 27 (multifactor)
and Passing & Bablok (method comparison) evaluation protocols. With the exception of evidence of systematic
erroneous sample predilution, overall results were favourable. Practicability of the Hitachi 911 was judged by
simulating daily routine. During a period of two weeks, daily urine samples were rerun on the Hitachi 911, leading
to a gain of about 50% in total processing time. It was concluded that the Hitachi 911 meets the requirements in
terms of analytical performance, reliability, versatility and speed for an analyzer to be used in a routine (urine)
setting, while having a distinct role in special (serum/whole blood) measurements.
Introduction
In our 1000 bed academic hospital a relatively large
number of urine analyses are performed daily. In looking
for a replacement for our dedicated analyzer for urinaly-
sis, we realized that not many data specifically concern-
ing urine are available as a basis for selection. The
choice of a new clinical chemistry analyzer requires the
objective assessment of its analytical and practical per-
formance. The former aspect is nowadays evaluated rou-
tinely with the use of one or more defined protocols and
algorithms. Based on previous experience (1) we have
decided to use evaluation protocols developed by the
American National Committee for Clinical Laboratory
Standards (NCCLS) for this study. Thus, NCCLS EP5-
T2 (EPS) and EP6-P (EP6) (2, 3) are one-at-a-time pro-
tocols used for testing imprecision and linearity, respec-
tively. The EPS protocol provides data on within-run,
run-to-run, day-to-day and total imprecision. Linearity
according to the EP6 protocol is either present or absent;
in the latter case, and for very precise assays (1), quanti-
fication of the deviation from linearity is possible with
the use of the data generated in the Kroll & Emancipator
algorithm (4, 5). The multifactor Krouwer 27 protocol
(6, 7) provides a simultaneous estimation of various
variables, including drift and carry-over. In addition,
methods can be compared according to Passing &
Bablok (8), relating the measurement of analytes by new
tests and/or analyzers to reference- or standard methods.
In the present study, we have used the above protocols
and algorithms to evaluate the performance of the Hi-
tachi 911 for assays measuring the following analytes:
sodium, potassium, calcium, phosphate, urea, creatinine,
glucose and total protein in urine. We also tested deter-
minations of lactate, iron, ferritin, haptoglobin, transfer-
rin, digoxin, vitamin B t 2 and folate in serum, and cyclo-
sporin in whole blood.
Next to the analytical quality, the practicability perfor-
mance of an analyzer plays an important role in the med-
ical laboratory. This was evaluated as follows: following
the manufacturers* instructions with respect to calibra-
tion and control frequency, we gained information on
various aspects of daily use of the Hitachi 911 in routine
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practice. For a period of 15 days and extrapolated to one
year, all routine urine samples were analyzed both using
die present methods and on the Hitachi 911, and turn-
around times were compared.
length grating device and twelve wavelength dependent diodes.
The instrument has flexible measuring windows allowing mea-
surements from 3 to 16.5 minutes. The measurement cycle is
20 seconds. All assays are performed at 37 °C. The reagents are
kept refrigerated at 10 °C.
Materials and Methods
Analyzer
The Hitachi 911 is a selective access analyzer with a capacity
of 35 different tests including 3 1SE methods. Its output rate is
360 tests per hour without 1SE and 720 tests per hour with ISE.
The ISE unit (indirect method) consists of three flow through
electrodes measuring sodium, potassium and chloride. By means
of two reagent-arms, one to four reagents can be added to a
sample. The optical system contains a halogen lamp, a wave-
Assays
The Hitachi 911 has so called defined channels for fixed applica-
tions (i. e. reagents provided by Boehringer Mannheim (BM)), and
open channels which give the user the opportunity to program ana-
lytical parameter settings freely. In total, 22 tests were installed
during the evaluation period (not all are discussed here) (tab. 1).
Urine assays were performed as described by the manufacturers
(tab. 1), except for the following cases which involved modifica-
tions in the settings defined by BM: calcium, glucose and total
protein. For calcium and glucose, this related to the calibration
methods used and was intended to improve the linearity and the
Tab. 1 Overview of assays investigated on the Hitachi 911. Sample volume (1*): 11 times prediluted sample; Sample volume
Suppliers: BM: Boehringer Mannheim; SYVA: Syva diagnostics. (2*): 26 times prediluted sample.
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linear range. In the original BM calcium determination, a 2 point
calibration was employed (0 and 2.5 mmol/1), whereas our applica-
tion involved a 5 point calibration (0, 1.25, 2.50, 3.75, and
5 mmol/1) calculated with linear regression. The BM glucose deter-
mination, also with a two point calibration (0 and 20 mmol/1), was
modified to involve a 5 point calibration (0, 5, 10, 25 and 50
mmol/1) calculated with cubic spline curve fitting. It is important
to note that as with patient samples, the calibration samples with
a glucose concentration of 25 mmol/1 or higher are automatically
prediluted (eight times, 30 μΐ + 210 μΐ) by the analyzer. The total
protein assay was modified with a third reagent (surfactant or Brij
35, 100 g/I final), to be added just before the cuvette washing step.
This reagent prevents contamination of the cuvettes with denatur-
ated proteins. Furthermore, one analyte was measured with dual
settings: ferritin, using two different calibration characteristics
namely
(a): „lower extended range"-measuring range 0-400 μg/l and 15 μΐ
sample volume (Ferritin l);
(b): „normal range"-measuring range 0-800 μg/l and 5 μΐ sample
volume (Ferritin 2).
Calibrat ion
An aqueous solution with the following composition was used for
the calibration of all urine analytes except sodium, potassium and
total protein: calcium 2.5 mmol/1, phosphate 25 mmol/1, urea 250
mmol/1, creatinine 8.75 mmol/1, glucose 5 and 200 mmol/1.
Sodium and potassium were calibrated with the BM Na+, KL+,
Cl~ standards.
Total protein was calibrated with Preciset U/CSF Protein (BM).
The following calibration materials were used for the serum tests:
CFAS protein (BM) for transferrin;
Preciset Ferritin (BM) for ferritin;
Orion calibration set (Orion Diagnostica, Espoo, Finland) for hap-
toglobin.
Digoxin and cyclosporin were calibrated with standards provided
by BM (CEDIA digoxin calibrators) and Syva Diagnostica (Syva
Diagnostica, San Jose, CA, USA), respectively.
Calibrators included in the CEDIA vitamin BI2 and folate test kit
(Microgenics Corporation, Concord, USA) were used for these an-
alytes.
Diluted lactic acid calibrator (BM) was used for the calibration
of lactate.
A Fe2+ solution from Baker chemicals (J. T. Baker Inc, USA) was
used as a calibrator for the determination of iron.
Imprecision protocol
Imprecision was tested according to the NCCLS EP5 protocol (2).
This protocol involves the measurement of analyte concentrations
at two levels, twice per day in duplicate for twenty days, followed
by calculation of within-run, between-run, run-tu-run and total im-
precision. As sample material various commercial control prepara-
tions were used:
Urinorm (Instruchemie, Hilversum, the Netherlands) for the urine
analytes;
Bio-Rad (Anaheim, CA, USA) Lyphocheck immunoassay control
levels 1, 2 and 3 for digoxin, ferritin and B12/folate;
Bio-Rad Liquicheck immunology control (human) levels 1 and 2
for haptoglobin and transferrin;
Βίο-Rad Lyphocheck whole blood control (human) levels 1, 2 and
3 for cyclosporin;
Precinorm U and Precipath U (BM) for iron;
Precinorm S and Precipath S (BM) for iron and lactate;
Precinorm TDM levels 1, 2 and 3 (BM) for digoxin, and
Precinorm P and Precipath P (BM) for haptoglobin, transferrin,
and ferritin.
Data were checked on outliers. When an outlier exceeded 5.5 times
the standard deviation of the test it was removed from the data
set (2).
Linearity
Linearity was tested according the NCCLS EP6 protocol (3). As
starting material for the urine analytes we used distilled water
("low") and an aqueous solution with appropriate concentrations
of the various analytes ("high"). Two human serum pools were
used ("low" and "high"). In some cases (ferritin and digoxin)
we had to spike the pooled serum with a stock solution. The
spiking method complied with the recommendations of the
NCCLS (3). Following the EP6 protocol, mixtures of the low
and high pool were made according to the following scheme:
low, 3 low + 1 high, 2 low + 2 high, 1 low + 3 high, high. The
5 level mixtures were then tested in two separate runs in quadru-
plicate. Data were plotted on an x,y linear-linear graph plot and
examined visually. In addition, the lack of fit (LOF) of the
linear model was determined mathematically with the
following algorithms:
LOF= RSS -TE
RSS = Residual sum of squares
RSS = [20 · Σ(Σν2) - (Σγ)2] / 20 - [20 - (Σ(χ · Σγ))
- (4 - Σχ) · (Σγ)]2 / 20 · [80 · Σχ2 - (4 - Σχ)2]
ΤΕ = Remainder sum of squares
TE = Σ[Σγ2 - (Σγ)2]
Then,
G = 5(LOF)/TE.
G was compared with the appropriate critical value of the F distri-
bution. If G was smaller than this critical value, the hypothesis of
a linear fit was not rejected. For very precise assays, data with
clinically acceptable linearity may be statistically declared non-lin-
ear (1). For this reason data from the EP6 observations were also
evaluated with the BMD-P5R polynominal regression calculation
program (BMDP Statistical Software Inc, USA) in order to obtain
1st, 2nd and 3rd order polynomes. The 3rd order polynomes were
imported in the Krott & Emancipator algorithm (4, 5) to obtain
quantitative measures of relative non-linearity. (Results < 2.5%,
from this algorithm, indicate a good linear fit).
Drift and carry-over
Drift and carry-over were evaluated according to the Krouwer 21
protocol (6, 7) with which one can discriminate between linear
drift, quadratic drift and concentration dependent drift. In addition,
this protocol quantitates the sample related carry-over indepen-
dently. A further result of the Krouwer 27 protocol provides an
estimation of the (non)-linearity and within-run imprecision. In sin-
gle runs three concentration levels of human serum [low (± 0),
medium (mixture of low and high) and high (maximum detectable
value)] were analyzed nine times in a sequence as prescribed. Dur-
ing the evaluation period the protocol was run in duplicate and the
results were interpreted separately.
Method comparison
The methods investigated on the Hitachi 911 (tab. 1) were com-
pared with those currently in use in our hospital. With the
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exception of sodium and potassium, urine assays were compared
with measurements using a continuous flow system (SMA II)
from Technicon (Technicon Ine, Tarrytöwn, New York, USA).
The following analytes were measured spectrophotometrically:
calcium (cresolphthalein complexing method), phosphate (molyb-
date UV method), urea (diacetylmonoxime method), creatinine
(alkaline pricrate method), and glucose (glucose oxidase-peroxi-
dase method), for more detailed descriptions see 1. c. (9). Sodium
and potassium measured on the Hitachi 911 by indirect ISE
were compared with flame emission spectrometry (SMA II).
Cyclosporin, digoxin and ferritin were compared with the radio-
immunoassay methods used in our hospital: cyclosporin was
determined with CYCLO-Trac® reagent provided by Incstar (Inc-
star, Minnesota, USA); reagents for the determination of digoxin
and ferritin were obtained from Diagnostic Products Corporation
(Diagnostic Products Corporation, Los Angeles, USA). Transfer-
rin and haptoglobin were compared with a nephelometric- and
turbidimetric method, respectively. For transferrin we used rea-
gents from Behringwerke (Behringwerke AG, Marburg, Ger-
many) adapted on a Behring nephelometer type 200. The turbidi-
metric determination of haptoglobin was performed using reagent
from Atlantic antibodies (Incstar, Minnesota, USA) adapted on
a COBAS BIO analyzer (Hoffmann La Roche, Switzerland). Iron
was measured using the same assay on both the Hitachi 911
and the Hitachi 747.
Statistics
For calculation of imprecision, linearity and Krouwer 27 parame-
ters, we used EVAL-KIT software (CKCHL, Tilburg, the Nether-
lands). Passing & Bablok mathematics (8) were used for the calcu-
lation of the method comparison parameters.
Practicability performance
Practicability assessment was performed in the following manner:
during a period of 15 working days we reanalysed our daily
urine routine samples on the Hitachi 911. All actions were
administrated such as number of (re)-calibrations because of




Results for vitamin BI2 and folate tests ate not included
in this paper. Although no proper methodology was
available, we nevertheless attempted to implement these
assays on the Hitachi 911. However, we did not succeed:
within-run coefficients of variation (CVs) were routinely
over 15%. This may relate to the fact that the Hitachi
911 does not allow the incubation times of over 15 min
that are recommended by the assay manufacturer. We
did not pursue this any further.
Imprecision
Data for the within-run, run-to-run, day-to-day and the
total imprecision for the urine analytes are summarized
in table 2. Imprecision data for the serum- and whole
blood tests are given in table 3. It should be noted that
the way imprecisions are calculated in this protocol (2)
may lead to within-run CVs being larger than day-to-day
CVs (e. g. calcium, 2.76 mmol/1). For all urine analytes,
acceptable CVs were found: total CVs were less than
3.0%, except for total protein (3.5% at the low control
level). With regard to creatinine, sodium and potassium,
these results are in agreement with those found in a re-
cently published multicentre Hitachi 911 evaluation pre-
dominantly focussed on serum and plasma analytes (10).
Some of the control materials appeared not to be suitable
for this kind of imprecision evaluation: for iron in Preci-
norm S and Precipath S inexplicable shifts in measured
levels were noticed, whereas the use of Precinorm U and
Precipath U resulted in CVs ranging from 1.1 to 3.2%,
Tab. 2 Imprecision of urine assays performed on the Hitachi 911. RD: creatinine, reduced volume; DL: creatinine, sample predilu-
Imprecision was quantitated using the NCCLS EP5-T2 protocol (2) tion.
as described in Materials and Methods. CV: coefficient of variation (for calculations, see figure 1).
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Tab. 3 Imprecision of serum and whole blood assays performed
on the Hitachi 911,
Imprecision was quantitated using the NCCLS EP5-T2 protocol (2)
as described in Materials and Methods.
Ferritin l: new set points; Ferritin 2: extended measuring range.
CV: coefficient of variation (for calculations, see figure 1). Infor-
mation on the controls is provided in Materials and Methods.
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comparable to previously published findings (10).
Furthermore, controls provided by Bio-Rad showed ex-
tremely high CVs for ferritin, haptoglobin and transfer-
rin, ranging from 9 to 16%. This is possibly caused by
instability of these materials. As an alternative, we mea-
sured these analytes in Precinorm P and Precipath P for
the EPS protocol; this reduced the variation to 2.5 to
5.5%. For cyclosporin only one set of controls is avail-
able: Bio-Rad Lyphochek whole blood control. The
rather high CVs for cyclosporin appear to be inherent
to this material, since calibrators and patient material
performed notably better. However, the EPS procedure
was not repeated with human material.
Linearity
Table 4 shows the results of the linearity evaluation for
those analytes tested. In the specified ranges, all tests
except the one for calcium were accepted as linear. For
urinary calcium, if measured according to the serum
specifications, linearity is lost above 5 mmol/1 (calcium
BM). Adaptation of the calcium calibration settings (see
Introduction) to a 5 point instead of a two point pro-
cedure improved linearity (by visual inspection) up to
approximately 9 mmol/1 (calcium AMC) (fig. 1). It
should be noted that although the glucose determination
was linear up to a theoretical concentration of 200
mmol/1, the measured values were incorrect (glucose
BM). Figure 2 illustrates that for all samples that were
prediluted (i.e. with first measurement values higher
than 20 mmol/1), final values of glucose concentration
were about 20% lower than expected. Apparently, sam-
ple predilution by the Hitachi 911 is characterized by a
systematic error. As a pragmatic solution, we have
adapted the calibration procedure to include standards
with values above 20 mmol/1, therefore requiring predi-
lution, resulting in a correct response in the higher con-
centration range (glucose AMC) (fig. 2). The success of
this problem solving procedure moreover indicates that
the dilution error relates to the sample and/or diluent
handling by the Hitachi 911. The error is therefore pre-
dicted to cause problems in any assay using sample pre-
dilution without calibration predilution.
Drift and carry-over
Drift and carry-over were tested for the same analytes
as in the linearity evaluation (tab. 4), according to the
Krouwer 27 protocol (6, 7). No significant drift or sam-
ple carry-over could be demonstrated with this sensitive
protocol (data not shown).
In addition, total protein determination was tested for
carry-over between serum and urine samples by using a
sample tray intermittently filled with human serum and
urine. Even in these extreme circumstances (total protein
concentrations varying between 0 and 2.5 g/1), no carry-
over was established.
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Tab. 4 Linearity.
K & E: Kroll & Emancipator relative non-linearity (4, 5);
6M: original settings according to Boehringer Mannheim;
AMC: changed settings as described in Materials and Methods.
Analyte
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Fig. l Improved linearity of modified calcium assay.
Five calcium level mixtures were prepared as prescribed for linear-
ity evaluation according to the NCCLS EP6 protocol (3), and
calcium was measured using either the original BM settings
(*; two point calibration) or the modified settings (O; five point








20 40 60 ΘΟ 100 1*1 140 1ft 1ΘΟ 200
Glucose (nominal) [mmol/l]
Fig. 2 Sample predilution error.
Five glucose level mixtures were prepared as prescribed for linear-
ity evaluation according to the NCCLS EP6 protocol (3). Glucose
was measured (involving sample predilution if [glucose] higher
than 20 mmol/1) using a two point calibration without calibrator
glucose concentrations above 20 mmol/1 and therefore without cali-
brator predilution (*), and using a five point calibration with cali-
brator glucose concentrations above 20 mmol/1 (o). (·): nominal
[glucose] = measured [glucose].
Method comparison
The results of the method comparisons according to
Passing & Bablok (8) are combined in table 5 includ-
ing the measured ranges. For each method, samples
were equally divided over the measuring range. In
general, correlations between measurements on the Hi-
tachi 911 and measurements with the currently used
methods were acceptable. An optimal correlation was
found for sodium and potassium measured with the
Hitachi 911 ISE in comparison with a flame emission
spectrometer. The glucose determinations correlated
poorly in the lower section of the measuring range
caused by the incapability of the SMA II to discrimi-
nate glucose values between 0-5 mmol/1. Data in this
concentration r nge were not included in the statisti-
cal evaluation.
Assessment of practibility
Practicability evaluation related to the performance of
the analyzer in daily routine use. This was investigated
as follows: complying with the recommendations of the
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Tab. 5 Method comparison for analytes measured on the Hitachi
911 and with reference or standard methods.
Method comparison was performed according to Passing & Bablok
(8) as described in Materials and Methods, n: number of samples;
Syx: standard error of estimated y; r: coefficient of correlation;
(U): urine; Ferritin (l): new set points; Ferritin (2): extended meas-
uring range.




























































1 - 9 mmol/1
1 - 50 mmol/1
50 - 500 mmol/1
0.7 - 22 mmol/1
0.1 - 7.5 g/l
5.0 - 219 mmol/i
4 -4500 μg/l
4 - 450 μg/l
4 -4500 μg/l
4 - 450 μg/l
4 -4500 μg/l
4 - 450 μg/l
0.7 - 5.0 g/l
1 - 70 μπιοΐ/ΐ
55 - 300μg/l
0.5 - 3 μg/l
0.03- 5 g/l
y = 0.997 χ + 1.001
y = 1.032 χ + 0.803
y = 0.953 χ - 0.043
y = 1.028x - 0.803
y = 1.058x + 0.460
y = 0.989 χ - 0.079
y = 0.945 χ - 0.053
y = 0.966 χ - 0.771
y = 0.939 χ - 4.636
y = 0.91 5 χ - 4.028
y = 1.046x -4.785
y = 1.039x - 4.879
y = 1.128x -l· 1.280
y = 1.154x + 0.298
y = 0.867 χ + 0.047
y = 0.987 χ - 0.312
y = 0.886 χ + 5.867
y = 1.063 χ - 0.098







































test- and analyzer manufacturer with respect to calibra-
tion frequencies and reagent stability (calibration was
every 24 hours and upon reagent renewal; controls were
included in every run with an interval of 30 samples),
all clinical requests for routine urine analyses were re-
analyzed on the Hitachi 911 for a period of 15 working
days. A daily average of 23 (SD = 13) patient urine
samples with 3 (SD = 3) test requests each were pro-
cessed. Data obtained on the reagents, calibrators and
controls used were extrapolated to a one-year period
using the total amount of test requests from 1993 (see
Materials and Methods). It was noted that for some tests
(e. g. total protein) the daily requests are less than the
samples necessary for calibration and control. As a re-
sult, the costs of these tests are strongly influenced by
the relatively numerous calibrations. The turnaround
time for the daily routine load of urine samples was two
hours, meaning a considerable shorter analyzer occu-
pancy than in our present laboratory setting with the
SMA II requiring four hours. Clearly, this leaves enough
room for the use of the Hitachi 911 in measurements of
various special serum and whole blood analytes, as in-
tended.
Overall conclusion
From the results presented it can be deduced that not-
withstanding its problems with sample predilution, the
Hitachi 911 is a good alternative to the SMA II for rou-
tine urine chemistry. With appropriate precision, all
measurements including total protein can be made from
a single tube. The analyzer has enough speed and versa-
tility to combine its use in urinalysis with the acceptable
performance of several homogeneous immunoassays
and other measurements of special serum or whole
blood analytes.
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